Brokerages Anticipate Medgenics Inc (GNMX) to Announce ($0.15) Earnings Per Share

Medgenics Inc (NASDAQ:GNMX) has been assigned an average broker rating score of 3.00 (Hold) from the one brokers that cover the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a hold recommendation. Medgenics’ rating score has declined by 20% in the last 90 days as a result of a number of analysts’ ratings changes.

Analysts have set a 12 month consensus price objective of $5.00 for the company and are forecasting that the company will post ($0.15) EPS for the current quarter, according to Zacks. Zacks has also given Medgenics an industry rank of 241 out of 265 based on the ratings given to its competitors.

How to Become a New Pot Stock Millionaire

A hedge fund recently raised its stake in Medgenics stock. Wells Fargo & Company MN boosted its holdings in shares of Medgenics Inc (NASDAQ:GNMX) by 433.7% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 130,662 shares of the biotechnology company’s stock after buying an additional 106,178 shares during the quarter. Wells Fargo & Company MN owned 0.35% of Medgenics worth $165,000 at the end of the most recent reporting period. 20.44% of the stock is owned by institutional investors.

GNMX stock traded down $0.11 during trading on Monday, reaching $1.90. The company had a trading volume of 143,539 shares, compared to its average volume of 217,783. The stock has a market capitalization of $119.27, a PE ratio of -2.29 and a beta of 1.03. Medgenics has a twelve month low of $0.98 and a twelve month high of $2.65.

COPYRIGHT VIOLATION WARNING: “Brokerages Anticipate Medgenics Inc (GNMX) to Announce ($0.15) Earnings Per Share” was reported by Week Herald and is the sole property of of Week Herald. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of US & international copyright law. The correct version of this piece of content can be viewed at

Medgenics Company Profile

Aevi Genomic Medicine, Inc, a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. The company's lead product candidates include AEVI-001, a glutamatergic neuromodulator, which is in Phase II/III SAGA trial for a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients with specific mutations in their metabotropic glutamate receptor gene network; and AEVI-002, an anti-light monoclonal antibody that is in Phase I clinical trial for use in severe pediatric onset crohn's disease.

Get a free copy of the Zacks research report on Medgenics (GNMX)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Medgenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medgenics and related companies with's FREE daily email newsletter.

Leave a Reply